Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22770575 | 1.00 | HPGD (0.51) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL15199122 | 0.96 | HPGD (0.48) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL15055293 | 0.94 | HPGD (0.52) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL15776468 | 0.94 | GAA (0.53) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL15776467 | 0.94 | GAA (0.53) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL15055295 | 0.94 | HPGD (0.52) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL10270236 | 0.91 | HPGD (0.44) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL4162821 | 0.88 | HPGD (0.44) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL4162817 | 0.88 | HPGD (0.44) | HPGDMAPTRECQLSETD7MEN1 | |
| SCHEMBL10441618 | 0.88 | HPGD (0.44) | HPGDMAPTRECQLSETD7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727380-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3727378-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11230547-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230547-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200392144-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200392144-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392144-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | HPGD 835/4885MAPT 4663/4885RECQL 516/4885 |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | HPGD 801/4885MAPT 4656/4885RECQL 703/4885 |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | HPGD 801/4885MAPT 4656/4885RECQL 703/4885 |
| US-11230547-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | HPGD 835/4885MAPT 4663/4885RECQL 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.